Sep 16, 2022 Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Sep 13, 2022 Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Aug 3, 2022 Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS